General Information of This Antigen (ID: TAR0LCGUX)
Antigen Name
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
Gene Name
VTCN1
Gene ID
79679
Synonym
B7 homolog 4;B7h.5;Immune costimulatory protein B7-H4;Protein B7S1;T-cell costimulatory molecule B7x
Sequence
MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGEDGILSCTFEP
DIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNV
QLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVV
WASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKV
TESEIKRRSHLQLLNSKASLCVSSFFAISWALLPLSPYLMLK

    Click to Show/Hide
Family
HIV-1 env protein family
Function
Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T- cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation.

    Click to Show/Hide
Uniprot Entry
VTCN1_HUMAN
HGNC ID
HGNC:28873
KEGG ID
hsa:79679
Each Antibody-drug Conjugate and Its Component Related to This Antigen
Full List of The ADC Related to This Antigen
The Numbers of ADCs, Their Three Components, Payload Targets, and Corresponding Diseases for This Antigens
Anti-B7-H4 IgG1k mAb
ADC Name Payload Target Linker ADC Info
LNCB74
Monomethyl auristatin E
Microtubule (MT)
β-glucuronide linker
Anti-B7H4 antibody
ADC Name Payload Target Linker ADC Info
BG-C9074
TOP1 inhibitor
DNA topoisomerase 1 (TOP1)
A cleavable linker
MHB009C [1]
MH30010008
DNA topoisomerase 1 (TOP1)
Undisclosed
B7-H4 2F9
ADC Name Payload Target Linker ADC Info
JP2024501894A5-11 [2]
Undisclosed
Undisclosed
Undisclosed
B7-H4 2F9V11 (K+)
ADC Name Payload Target Linker ADC Info
JP2024501894A5-5 [2]
Undisclosed
Undisclosed
Undisclosed
JP2024501894A5-6 [2]
Undisclosed
Undisclosed
Undisclosed
B7-H4 2F9V17 (K+)
ADC Name Payload Target Linker ADC Info
JP2024501894A5-7 [2]
Undisclosed
Undisclosed
Undisclosed
B7-H4 2F9V18
ADC Name Payload Target Linker ADC Info
JP2024501894A5-20 [2]
Undisclosed
Undisclosed
Undisclosed
Emiltatug
ADC Name Payload Target Linker ADC Info
Emiltatug ledadotin
AF-HPA
Microtubule (MT)
A cleavable ester linker
Felmetatug
ADC Name Payload Target Linker ADC Info
Felmetatug vedotin
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
Mocertatug
ADC Name Payload Target Linker ADC Info
Mocertatug rezetecan
SHR9265
DNA topoisomerase 1 (TOP1)
Mc-Gly-Gly-Phe-Gly
Nimotuzumab
ADC Name Payload Target Linker ADC Info
CN112341521B+ADC-1 [3]
Undisclosed
Undisclosed
Undisclosed
CN112341521B+ADC-2 [3]
Undisclosed
Undisclosed
Undisclosed
CN112341521B+ADC-3 [3]
Camptothecin
DNA topoisomerase 1 (TOP1)
CN112341521B+Linker3
CN112341521B+ADC-4 [3]
Camptothecin
DNA topoisomerase 1 (TOP1)
Undisclosed
CN112341521B+ADC-5 [3]
Topo1 inhibitor D
DNA topoisomerase I (TOP1)
CN112341521B+Linker3
CN112341521B+ADC-6 [3]
Topo1 inhibitor D
DNA topoisomerase I (TOP1)
Undisclosed
CN112341521B+ADC-7 [3]
Topo1 inhibitor D
DNA topoisomerase I (TOP1)
Undisclosed
CN112341521B+ADC-8 [3]
Undisclosed
Undisclosed
Undisclosed
CN112341521B+ADC-9 [3]
Undisclosed
Undisclosed
Undisclosed
CN112341521B+ADC-10 [3]
Undisclosed
Undisclosed
CN112341521B+Linker10
CN112341521B+ADC-11 [3]
CN112341521B+Payload11
DNA topoisomerase I (TOP1)
CN112341521B+Linker11
CN112341521B+ADC-12 [3]
CN112341521B+Payload11
DNA topoisomerase I (TOP1)
CN112341521B+Linker12
CN112341521B+ADC-13 [3]
Undisclosed
Undisclosed
CN112341521B+Linker12
CN112341521B+ADC-14 [3]
Undisclosed
Undisclosed
CN112341521B+Linker12
CN112341521B+ADC-15 [3]
Undisclosed
Undisclosed
CN112341521B+Linker11
CN112341521B+ADC-16 [3]
Undisclosed
Undisclosed
CN112341521B+Linker11
CN112341521B+ADC-17 [3]
Undisclosed
Undisclosed
CN112341521B+Linker10
CN112341521B+ADC-18 [3]
Undisclosed
Undisclosed
CN112341521B+Linker11
CN112341521B+ADC-19 [3]
Undisclosed
Undisclosed
Undisclosed
CN112341521B+ADC-20 [3]
Undisclosed
Undisclosed
CN112341521B+Linker20
CN112341521B+ADC-21 [3]
Undisclosed
Undisclosed
CN112341521B+Linker20
CN112341521B+ADC-22 [3]
Undisclosed
Undisclosed
CN112341521B+Linker22
CN112341521B+ADC-23 [3]
Undisclosed
Undisclosed
CN112341521B+Linker22
CN112341521B+ADC-24 [3]
Undisclosed
Undisclosed
CN112341521B+Linker24
CN112341521B+ADC-25 [3]
Undisclosed
Undisclosed
Undisclosed
CN112341521B+ADC-26 [3]
Undisclosed
Undisclosed
CN112341521B+Linker26
CN112341521B+ADC-27 [3]
Undisclosed
Undisclosed
CN112341521B+Linker22
CN112341521B+ADC-28 [3]
Undisclosed
Undisclosed
CN112341521B+Linker24
CN112341521B+ADC-29 [3]
Undisclosed
Undisclosed
CN112341521B+Linker26
CN112341521B+ADC-30 [3]
CN112341521B+Payload30
Undisclosed
CN112341521B+Linker26
CN112341521B+ADC-31 [3]
CN112341521B+Payload30
Undisclosed
CN112341521B+Linker31
CN112341521B+ADC-32 [3]
Undisclosed
Undisclosed
CN112341521B+Linker31
CN112341521B+ADC-33 [3]
Undisclosed
Undisclosed
Undisclosed
CN112341521B+ADC-34 [3]
Undisclosed
Undisclosed
CN112341521B+Linker10
Puxitatug
ADC Name Payload Target Linker ADC Info
Puxitatug samrotecan
AZ14170132 (AZ0132)
DNA topoisomerase 1 (TOP1)
Mal-PEG8-Val-Ala
Thio Hu Anti-B7-H4 1D11v1.9_VarD LC K149C
ADC Name Payload Target Linker ADC Info
CN118436801A PAC 2 [4]
undisclosed
Undisclosed
Mc-Val-Cit-PABC
CN118436801A PAC 4 [4]
undisclosed
Undisclosed
Mc-Val-Cit-PABC
XMT-1603 (B7-H4 2F9V7)
ADC Name Payload Target Linker ADC Info
JP2024501894A5-3 [2]
Undisclosed
Undisclosed
Undisclosed
JP2024501894A5-4 [2]
Undisclosed
Undisclosed
Undisclosed
JP2024501894A5-13 [2]
Undisclosed
Undisclosed
Undisclosed
XMT-1604 (B7-H4 2F9V18)
ADC Name Payload Target Linker ADC Info
JP2024501894A5-2 [2]
Undisclosed
Undisclosed
Undisclosed
JP2024501894A5-12 [2]
Undisclosed
Undisclosed
Undisclosed
JP2024501894A5-15 [2]
Undisclosed
Undisclosed
Undisclosed
Undisclosed
ADC Name Payload Target Linker ADC Info
BA-3151 [5]
Undisclosed
Undisclosed
Undisclosed
References
Ref 1 Preclinical development of MHB009C: A novel anti-B7-H4 ADC with a potent topoisomerase I inhibitor
Ref 2 B7h4 targeting antibody-drug conjugate and its use
Ref 3 Small-molecule active compounds and their antibody conjugates, preparation methods and medical uses
Ref 4 PROTAC antibody conjugates and methods of use
Ref 5 Bioatla biotechnology company announcement; 2021